n-acetyl-4,4'-diaminodiphenylmethane, also known as N-acetyl-MDA, is an organic compound that has been studied for its potential applications in various fields. It is a derivative of the diamine 4,4'-diaminodiphenylmethane, which is a key intermediate in the synthesis of polyurethanes. The acetylation of 4,4'-diaminodiphenylmethane leads to the formation of n-acetyl-4,4'-diaminodiphenylmethane, which exhibits different properties compared to its precursor. It is a colorless to pale yellow solid with a melting point of 128-130 °C. While the compound is not widely studied, it has been explored for its potential as a monomer in the synthesis of polyurethanes, as well as its potential use as a reagent in organic synthesis. It is believed that n-acetyl-4,4'-diaminodiphenylmethane may contribute to improved properties in polymers, such as enhanced thermal stability and improved mechanical strength. Further research is needed to fully understand the potential applications of this compound.'
N-acetyl-4,4'-diaminodiphenylmethane: major metabolite of DDM in urine; used for monitoring workers exposed to DDM [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 97263 |
| SCHEMBL ID | 13343448 |
| MeSH ID | M0143192 |
| Synonym |
|---|
| nsc109735 |
| 24367-94-0 |
| nsc-109735 |
| ccris 5691 |
| acetamide, n-(4-((4-aminophenyl)methyl)phenyl)- |
| nsc 109735 |
| n-acetyl-4,4'-diaminodiphenylmethane |
| n-[4-[(4-aminophenyl)methyl]phenyl]acetamide |
| AKOS002813421 |
| n-acetyl-4,4'-methylenedianiline |
| SCHEMBL13343448 |
| DTXSID00179109 |
| AS-66090 |
| n-{4-[(4-aminophenyl)methyl]phenyl}acetamide |
| n-(4-(4-aminobenzyl)phenyl)acetamide |
| acetamide,n-[4-[(4-aminophenyl)methyl]phenyl]- |
| mfcd02752271 |
| D80956 |
| CS-0199053 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " The dose-response relationships for hemoglobin adducts and urine metabolites were non-linear over this dose range." | ( Hemoglobin adducts and urine metabolites of 4,4'-methylenedianiline after 4,4'-methylenediphenyl diisocyanate exposure of rats. Heinrich, U; Henschler, D; Hoymann, HG; Sabbioni, G; Schütze, D; Sepai, O, 1995) | 0.29 |
| " Additional groups were dosed by gavage and intraperitoneal injection." | ( Analysis of biomarkers in rats and dogs exposed to polymeric methylenediphenyl diisocyanate (pMDI) and its glutathione adduct. Brown, WE; Hext, P; Leibold, E; Leng, G; Pauluhn, J, 2006) | 0.33 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (40.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.31) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||